Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

被引:73
作者
Saciuk, Yaki [1 ]
Kertes, Jennifer [1 ]
Stein, Naama Shamir [1 ]
Zohar, Anat Ekka [1 ]
机构
[1] Maccabi HealthCare Serv, Div Data & Digital Hlth, Tel Aviv, Israel
关键词
vaccine effectiveness; COVID-19; SARS-CoV-2; Pfizer-BioNTech vaccine; mRNA BNT162b2; COVID-19; VACCINE; ISRAEL; IMPACT;
D O I
10.1093/infdis/jiab556
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January-February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August-October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%-93.2%) and adjusted VE was 89.1% (95% CI, 87.5%-90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.
引用
收藏
页码:30 / 33
页数:4
相关论文
共 9 条
[1]   Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].
Bar-On, Yinon M. ;
Goldberg, Yair ;
Mandel, Micha ;
Bodenheimer, Omri ;
Freedman, Laurence ;
Kalkstein, Nir ;
Mizrahi, Barak ;
Alroy-Preis, Sharon ;
Ash, Nachman ;
Milo, Ron ;
Huppert, Amit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400
[2]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[3]   Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [J].
Haas, Eric J. ;
Angulo, Frederick J. ;
McLaughlin, John M. ;
Anis, Emilia ;
Singer, Shepherd R. ;
Khan, Farid ;
Brooks, Nati ;
Smaja, Meir ;
Mircus, Gabriel ;
Pan, Kaijie ;
Southern, Jo ;
Swerdlow, David L. ;
Jodar, Luis ;
Levy, Yeheskel ;
Alroy-Preis, Sharon .
LANCET, 2021, 397 (10287) :1819-1829
[4]  
Kertes J, 2021, EMERG INFECT DIS, V28, P338, DOI [10.1101/2021.09.01.21262957, DOI 10.1101/2021.09.01.21262957]
[5]   COVID-19 vaccine impact in Israel and a way out of the pandemic [J].
Leshem, Eyal ;
Wilder-Smith, Annelies .
LANCET, 2021, 397 (10287) :1783-1785
[6]  
Patalon T, 2021, SHORT TERM REDUCTION, DOI 10.1101/2021.08.29.21262792
[7]   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].
Polack, Fernando P. ;
Thomas, Stephen J. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Perez, John L. ;
Perez Marc, Gonzalo ;
Moreira, Edson D. ;
Zerbini, Cristiano ;
Bailey, Ruth ;
Swanson, Kena A. ;
Roychoudhury, Satrajit ;
Koury, Kenneth ;
Li, Ping ;
Kalina, Warren V. ;
Cooper, David ;
Frenck, Robert W., Jr. ;
Hammitt, Laura L. ;
Tureci, Ozlem ;
Nell, Haylene ;
Schaefer, Axel ;
Unal, Serhat ;
Tresnan, Dina B. ;
Mather, Susan ;
Dormitzer, Philip R. ;
Sahin, Ugur ;
Jansen, Kathrin U. ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615
[8]   Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine [J].
Tanne, Janice Hopkins .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 371 :m4799
[9]   Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study [J].
Tartof, Sara Y. ;
Slezak, Jeff M. ;
Fischer, Heidi ;
Hong, Vennis ;
Ackerson, Bradley K. ;
Ranasinghe, Omesh N. ;
Frankland, Timothy B. ;
Ogun, Oluwaseye A. ;
Zamparo, Joann M. ;
Gray, Sharon ;
Valluri, Srinivas R. ;
Pan, Kaije ;
Angulo, Frederick J. ;
Jodar, Luis ;
McLaughlin, John M. .
LANCET, 2021, 398 (10309) :1407-1416